A Phase 2b, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as a Chemoablation Agent in Patients With Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence

Trial Profile

A Phase 2b, Single Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as a Chemoablation Agent in Patients With Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2018

At a glance

  • Drugs Mitomycin (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors UroGen Pharma
  • Most Recent Events

    • 11 Jul 2018 According to an UroGen Pharma media release, the company has submitted an IND application for UGN-102 (VesiGel, mitomycin gel for intravesical instillation) for the treatment of patients with low-grade non-muscle invasive bladder cancer (LG NMIBC) to the US FDA and if accepted, the company expects to begin this trial in Q3 2018.
    • 24 Jun 2018 Status changed from planning to not yet recruiting.
    • 15 May 2018 According to an UroGen Pharma media release, this study is expected to start in mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top